ArticleInvestigative ophthalmology & visual science2025
Preclinical Assessment of Mitochondrial-Targeted ND4 Gene Therapy for Leber Hereditary Optic Neuropathy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Deep Learning-Driven Transmission Electron Microscopy Analysis of Murine Optic Nerve Myelinated Axons.Ophthalmology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Purpose: The purpose of this study was to establish preclinical safety data to advance mitochondrial targeted AAV-delivered human ND4 (MTSAAV/hND4) for treatment of Leber Hereditary Optic Neuropathy (LHON). Methods: MTSAAV/hND4 was bilaterally injected into mouse eyes to evaluate potential adverse effects on visual function using serial pattern electroretinograms (PERGs) and spectral-domain optical coherence tomography (SD-OCT). In rats, MTSAAV/hND4 was administered unilaterally to assess toxicity, biodistribution, and neutralizing antibody levels. Control groups include PBS-injected and untreated naïve mice and rats. Results: No significant adverse effects on visual function were observed in mice treated with MTSAAV/hND4. Retinal thickness remained largely stable, with only a transient, benign increase in RNFL-IPL thickness observed in the low-dose group at 1 month. Postmortem analysis showed no significant differences in RGC density among MTSAAV/hND4-injected mice, PBS-injected controls, and naïve controls (P = 0.214), and axons morphology and distribution were preserved. In rats, viral DNA was primarily detected in the injected eyes with copy number of 4.63 × 10⁴ at day 7 and 4.94 × 103 at day 90 per 100 ng of genomic DNA. Viral DNA levels in non-ocular tissues were low (<500 copies). Histopathological analysis showed no vector-related toxicity. At 6 months post-injection, overall hematological parameters remained within normal limits. All MTSAAV/hND4-injected rats seroconverted by day 90, with neutralizing antibody titers reaching 1:1280. Conclusions: Intravitreal delivery of MTSAAV/hND4 in rodents resulted in favorable biodistribution, with vector DNA largely confined to the injected eye and minimal systemic exposure. No vector-related adverse effects were observed based on functional, anatomic, and histopathological assessments, supporting the ocular safety of this gene therapy strategy. These findings provide preclinical evidence supporting the advancement of MTSAAV-mediated ND4 gene therapy toward clinical trials for LHON.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.